Arcturus Therapeutics Reports Q3 2025 Net Loss of $13.5M, Progresses ARCT-032 and ARCT-810 Programs

Arcturus Therapeutics Holdings Inc.

2025-Q3 EPS reported -$1.35 revenue$74,835,000

Q3 2025 revenue was $17.2M, down $24.5M from prior year; net loss $13.5M ($0.49 per share) vs $6.9M loss in Q3 2024.
ARCT-032 Phase 2 interim data: inhaled 10mg daily over 28 days well tolerated; mucus burden reduced in 4 of 6 Class I CF adults per HRCT scans.
Company plans a 12-week safety and efficacy study of ARCT-032 in up to 20 CF participants starting H1 2026.
FDA changes delayed U.S. BLA filing for KOSTAIVE indefinitely; additional cost reductions planned in Q4 2025 to extend cash runway into 2028.
ARCT-2304 pandemic flu vaccine candidate induced humoral immune response after single dose at all tested levels, supporting further development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.